DeCure for Epidermolysis bullosa simplex 1A, generalized severe
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for epidermolysis bullosa simplex 1A, generalized severe — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpidermolysis bullosa simplex 1A, generalized severe maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epidermolysis bullosa simplex 1a, generalized severe is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
keratin 10 (KRT10) — KRT10 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet bogdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6UUI · 2.069 Å · ligand octyl beta-D-glucopyranoside (BOG). Experimental structure, not a prediction.
What the evidence adds up to
Epidermolysis bullosa simplex (EBS) is a rare autosomal dominant genetic condition in which bullous lesions larger than 0.5 cm appear on skin exposed to mechanical friction or minor trauma. Prevention of these lesions begins with family and patient education, and infants require greater care and control of their environment. Every individual with EBS receives a treatment plan specifically tailored to the severity and extent of skin involvement. A 2022 review article provides a comprehensive overview of EBS, including diagnostic approach, preventative considerations, and current treatments, but reports no new trial data or quantitative outcomes.
A 2025 dermatologist’s perspective notes that hereditary epidermolysis bullosa is a genetically caused disease of skin fragility. Mutations have been identified in at least 20 different genes, resulting in conformational changes or absence of cytoskeletal, cell-matrix, or cell-adhesion proteins in the skin. Based on these molecular abnormalities, four basic disease types are distinguished: simplex, junctional, and dystrophic hereditary epidermolysis bullosa, and Kindler syndrome, with at least 30 clinically distinct subtypes. In severe forms, complications can arise on the skin, mucous membranes, or nail adnexa. No treatment efficacy data or patient numbers are given.
A 2016 study identified a possible cause of chronic itching in EBS, published in the Journal of Allergology and Clinical Immunology. The work, by cell biologist Thomas Magin at the University of Leipzig with colleagues in Freiburg and Marburg, found that itching worsens the condition. No drug intervention, response rates, or survival figures are reported in any of these abstracts. What is still missing is any controlled trial of a repurposed drug, quantitative evidence of symptom reduction, and patient stratification by genetic subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the Dermatology Nurses’ Association · 2022 · 1 citations
Epidermolysis Bullosa Simplex
AbstractABSTRACT Epidermolysis bullosa simplex (EBS) is a rare autosomal dominant, genetic condition where bullous lesions, larger than 0.5 cm, affect an area of the skin that is exposed to mechanical friction or minor trauma. Prevention of the bullous lesions starts with family and patient education, with infants requiring greater care and control of their environment. Every individual with EBS will have a treatment plan specifically tailored to the severity and extent of skin involvement. This article provides a comprehensive overview of EBS, including diagnostic approach, preventative considerations, and current treatments.
Slovenska pediatrija revija pediatrov Slovenije in specialistov šolske ter visokošolske medicine Slovenije · 2025 · 0 citations · open access
EPIDERMOLYSIS BULLOSA HEREDITARIA: A DERMATOLOGIST‘S PERSPECTIVE AND NEWLY TREATMENT APPROACHES
AbstractIzvleekDedna bulozna epidermoliza je genetsko povzroena bolezen krhkosti koe.Doslej so bile identificirane mutacije, ki vkljuujejo vsaj 20 razlinih genov s posledino konformacijsko spremenjenostjo ali odsotnostjo beljakovin citoskeleta, celinega matriksa ali beljakovin medceline adhezije v koi.Na osnovi genetsko povzroenih molekularnih nepravilnosti in zato nastalih razslojevanj konega tkiva razlikujemo 4 osnovne tipe bolezni: simpleks, junkcijsko in distrofino dedno bulozno epidermolizo ter Kindlerjev sindrom; v sklopu osnovnih tipov poznamo vsaj 30 klinino razlinih podtipov bolezni.Pri tejih oblikah dednih buloznih epidermoliz se lahko pojavljajo zapleti na koi, sluznicah ali konih adne-
Epidermolysis bullosa simplex – Neue Hinweise auf Juckreizursache
AbstractEine der Erkrankungen, die durch Juckreiz verschlimmert wird, ist Epidermolysis bullosa simplex (EBS). Zellbiologe Prof. Thomas Magin von der Universität Leipzig hat in Zusammenarbeit mit Kollegen aus Freiburg und Marburg erstmals eine mögliche Ursache für den chronischen Juckreiz bei EBS identifiziert und dies im Journal of Allergology and Clinical Immunology publiziert. (DOI: 10.1016/j.jaci.2016.04.046)
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
